The Study
TRIAC Therapy Relieves Hyperthyroid Symptoms, Lowering T4, T3, and Metabolic Rate in Resistance to Thyroid Hormone β
This study watched 8 people who took a new medicine and saw that their symptoms got better afterward. But we don’t know if the medicine caused the improvement—maybe they got better on their own, or something else changed. It’s like noticing your headache went away after you drank water—you can’t be sure the water fixed it.
Analysis score
Maximum 36 for a cohort study.
Where the score came from
Some people have a rare condition where their body thinks it has too much thyroid hormone, even when it doesn't — causing anxiety, fast heartbeat, and weight loss. This study tested a special pill called TRIAC to see if it could fix that.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 530 / 100
Quality score
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — their symptoms improved a lot, and their heart and metabolism stayed safe, even though their thyroid hormone levels dropped.
- 2After taking TRIAC for about 3 years, 7 out of 8 people had normal thyroid hormone levels, their symptom score dropped from 17.5 to 6 (like going from very sick to almost normal), and their heart rate and cholesterol didn't get worse.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of clinical endocrinology and metabolism
Year
2025
Authors
C. Moran, J. Martin-Grace, Greta Lyons, Laura Watson, Kevin Taylor, Susan Oddy, David Halsall, Krishna Chatterjee
Related Content
Claims (6)
Hyperthyroidism causes a higher resting metabolic rate, which results in a faster heart rate, shaking, weight loss without trying, greater hunger, and diarrhea.
In adults with resistance to thyroid hormone β, long-term TRIAC therapy does not change total cholesterol, triglycerides, fasting glucose, insulin resistance, or bone mineral density.
In adults with resistance to thyroid hormone β, treatment with TRIAC does not alter sleeping heart rate or plasma NT-proBNP levels.
In adults with resistance to thyroid hormone β, taking TRIAC orally at 1.3–3.0 mg per day for about 40 months is associated with lower hyperthyroid symptom scores and normalization of free T4 and total T3 levels in most patients, without an increase in TSH.
In adults with resistance to thyroid hormone β, treatment with TRIAC results in normalization of serum free T4 and total T3 levels in 88% of cases without elevating serum TSH.
In adults with resistance to thyroid hormone β, treatment with TRIAC is associated with a decrease in resting energy expenditure toward normal values, though the change was not statistically significant.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.